nimesulide has been researched along with Cystic Fibrosis of Pancreas in 3 studies
nimesulide: structure
nimesulide : An aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups.
| Excerpt | Relevance | Reference |
|---|
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chung, WJ | 1 |
| Goeckeler-Fried, JL | 1 |
| Havasi, V | 1 |
| Chiang, A | 1 |
| Rowe, SM | 1 |
| Plyler, ZE | 1 |
| Hong, JS | 1 |
| Mazur, M | 1 |
| Piazza, GA | 1 |
| Keeton, AB | 1 |
| White, EL | 1 |
| Rasmussen, L | 1 |
| Weissman, AM | 1 |
| Denny, RA | 1 |
| Brodsky, JL | 1 |
| Sorscher, EJ | 1 |
| Lands, LC | 1 |
| Stanojevic, S | 1 |
| Ciabattoni, G | 1 |
| Davì, G | 1 |
| Collura, M | 1 |
| Iapichino, L | 1 |
| Pardo, F | 1 |
| Ganci, A | 1 |
| Romagnoli, R | 1 |
| Maclouf, J | 1 |
| Patrono, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Role of IL-17 Neutrophils in CF Lung Inflammation[NCT02025829] | 14 participants (Actual) | Observational | 2014-02-28 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
In the Exacerbation/IV Antibiotics Cohort--Subjects will serve as their own controls. The percentage of neutrophils (in sputum) positive for IL-17 was determined by flow cytometry for each subject at the beginning and end of treatment for a pulmonary exacerbation. Sputum IL-17 neutrophil counts will be compared to the change in lung function (FEV1) as determined by spirometry (American Thoracic Society standards). (NCT02025829)
Timeframe: End of Treatment, two weeks. Samples will be obtained from each study volunteer at the beginning of IV antibiotic treatment and at the completion of antibiotic treatment for a pulmonary exacerbation
| Intervention | % of neutrophils positive for IL-17 (Mean) |
|---|---|
| Begining of Exacerbation | 55 |
| End of Exacerbation | 4 |
In the Exacerbation/IV Antibiotics Cohort--Measurement of sputum inflammatory mediators by multiplex assay for IL-1β, IL-6, IL-8, and IL-17A. Neutrophil elastase determined by colorimetric assay. Measurements at the beginning of IV antibiotic treatment and after 2 weeks antibiotic treatment for a pulmonary exacerbation (NCT02025829)
Timeframe: End of Treatment, two weeks. Samples will be obtained from each study volunteer at the beginning of IV antibiotic treatment and at the completion of antibiotic treatment for a pulmonary exacerbation
| Intervention | pg/ml (Mean) | ||||
|---|---|---|---|---|---|
| IL-1b (pg/ml) | IL-6 (pg/ml) | IL-8 (pg/ml) | IL-17 (pg/ml) | Neutrophil elastase activity (pg/ml) | |
| Begining of Exacerbation | 2313 | 53 | 5785 | 302 | 195 |
| End of Exacerbation | 757 | 37 | 3428 | 147 | 53 |
1 review available for nimesulide and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Clarithromycin; Cystic Fibrosis; Huma | 2013 |
2 other studies available for nimesulide and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regu | 2016 |
In vivo lipid peroxidation and platelet activation in cystic fibrosis.
Topics: Adolescent; Adult; Child; Cyclooxygenase Inhibitors; Cystic Fibrosis; Dinoprost; F2-Isoprostanes; Fe | 2000 |